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Endometriosis is a chronic gynecological disorder afflicting reproductive-age women. 
Different pathogenic hypotheses have been formulated to explain the development of this 
disease. According to a vast body of evidence, viable endometrial cells reach the abdominal 
cavity during menstruation via trans-tubal retrograde blood reflux, and implant on the pelvic 
peritoneum. Their metabolic activity at ectopic sites causes inflammation, adhesion 
formation, and fibrosis of affected structures. This may cause pain symptoms and infertility, 
with repercussions on physical and emotional well-being, sexual function, and health-related 
quality of life. Endometriosis prevalence rate among 15-49 year women is around 3-5% [1]. 
In case of women seeking conception, clinicians should consider that a satisfactory 
balance between adequate control of pain symptoms and optimization of reproductive 
performance is sometime difficult to attain. When a shared decision is to be taken, also the 
costs of surgery and assisted reproductive techniques in different clinical conditions should be 
compared and taken into account. However, diverse treatment alternatives are available also 
for women not wishing pregnancy. Thus, we here evaluate those factors that may influence 
the value, burden, and cost of chronic management in women with endometriosis-associated 
pelvic pain and not wanting a pregnancy immediately or in the future.  
1.  Factors impacting on the financial burden of endometriosis   
Direct and indirect costs of endometriosis management in western countries are variable, as 
several factors influence reported estimates, including national healthcare system type, and 
local economic and social context. Average total direct and indirect costs per patient per year 
range, respectively, from $1109 (Canada) to $12118 (USA), and from $3314 (Austria) to 
$15737 (USA) [2]. 
 Diverse diagnostic and therapeutic strategies associated with very different 
management costs can be adopted in women with symptomatic endometriosis who do not 
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seek a pregnancy. The resulting annual national economic burden is thus highly variable. This 
is particularly important when considering that the disease may cause symptoms for decades. 
Several international gynecological societies have issued guidelines for the treatment of 
endometriosis-associated pain [3-6], but strong recommendations may be hampered by a 
dearth of comparative effectiveness research concerning several clinical issues [6].  
 This permits ample margins of therapeutic individualism, with a potential risk of 
overmedicalization. Indeed, several stakeholders may profit from overdiagnosis and 
overtreatment of endometriosis. Industry influence, hospital revenues, competing interests, 
self-referrals, and fee-for-service payment systems, in addition to insufficient knowledge of 
healthcare economic evaluation, may impact on the financial burden shouldered by families 
and health services [7,8].  
 To maximize the benefit from a fixed sum of money, or minimize the resources 
required for a defined benefit, low-value diagnostic and therapeutic interventions (i.e., with an 
unfavorable balance between potential benefits, potential harms, and cost) should be 
identified based on the available evidence, and de-implemented.  
 According to the Practice Committee of the American Society for Reproductive 
Medicine, in symptomatic women not seeking a conception, ‘‘endometriosis should be viewed 
as a chronic disease that requires a life-long management plan with the goal of maximizing 
the use of medical treatment and avoiding repeated surgical procedures’’ [5]. This 
recommendation takes into account that even adequate excisional surgery is associated with a 
symptom and lesion recurrence rate of about 10% per year, and that the outcomes of 
reoperations are generally less favorable compared with those of first-line procedures [9,10].  
 On the other hand, medical treatments for endometriosis are symptomatic and not 
curative, and may be needed for years or until pregnancy is desired. Consequently, not only 
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the efficacy of medications, but also their cost, safety, and tolerability, must be carefully 
considered. Also women with endometriosis may choose to forgo care when faced with 
unaffordable options [8,11]. 
 Recently, the UK's National Institute for Health and Care Excellence (NICE) has 
issued a guideline on diagnosis and management of endometriosis that, for the first time, 
includes explicit consideration of cost effectiveness [12]. This guidance may help assess the 
overall financial burden of tests and treatments in combination with their clinical benefits and 
harms, and may inform resource allocation, thus increasing the efficiency of healthcare 
utilization. 
 
2. Reducing low-value diagnostic modalities 
Laparoscopy with positive histology on biopsy specimens is still considered the diagnostic 
gold standard [4-6]. However, systematically performing a laparoscopy in patients with pain 
symptoms suggestive of endometriosis implies high costs and increases morbidity, and 
prevents women from choosing between medical and surgical therapy. Thus, implementation 
of reliable non-surgical diagnostic modalities would have important clinical and economic 
implications [7]. 
 The main endometriotic phenotypes are superficial peritoneal implants, ovarian cysts, 
and deep lesions infiltrating the vagina, the rectosigmoid, the bladder, and the parametria. 
Transvaginal ultrasonography (TVUS) has a demonstrated high overall accuracy as a test for 
the identification of ovarian and deep endometriotic lesions, approaches the criteria for 
replacement of laparoscopy, and satisfies the criteria for triage (i.e., a test that should be used 
as the initial step in a diagnostic pathway) [8,13,14]. 
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 Magnetic resonance imaging (MRI) may add useful information only in selected 
circumstances, as in case of doubtful TVUS findings or before high-risk surgery for excision 
of deep lesions. The NICE Guideline Committee discourages the use of MRI as a first-line 
test and recommends fewer MRIs than current practice [12].  
 Only superficial peritoneal implants cannot be diagnosed by imaging techniques. 
However, it has never been demonstrated that elimination of early lesions would benefit most 
patients in terms of disease progression, pain recurrence, and reproductive outcome [7]. 
Women should be informed that safe and inexpensive medications would likely relieve their 
complaints, that a laparoscopy should be indicated in non-responders, and that not removing 
early, limited implants would not necessarily translate into worse prognosis, provided 
adequate medical suppression is consistently used [7,8].  
 A diagnostic delay of 6-8 years has been repeatedly reported [2]. However, this is 
likely the result of inadequate awareness and knowledge of endometriosis, rather than of not 
timely performing a diagnostic laparoscopy in all women with pelvic pain. Even when 
physical examination and TVUS are negative, endometriosis can and should be suspected and 
treated medically without delay, independently of direct lesion visualization [7]. The burden 
of undiagnosed and untreated endometriosis is undefined [2], but prompt empirical hormonal 
therapy (i.e., based on symptoms rather than definitive diagnosis), in addition to providing 
rapid symptom relief in most women, could also substantially reduce indirect costs.  
3. Reducing low-value medical treatment 
According to international guidelines, pain relief obtained with various compounds is similar, 
whereas safety and costs differ [3-6,12]. In Italy, the cost of one year of treatment with the 
most widely used medications for endometriosis varies widely, ranging from €17-£16-$20 to 
€1840-£1693-$2190 (Table 1). The cost of the GnRH antagonist elagolix, a new 
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hypoestrogenizing drug that soon will be launched on the market, is currently unknown. Of 
relevance here, good efficacy may translate into sub-optimal effectiveness when women have 
to pay for a novel, expensive therapy [11]. 
 In order to improve the efficiency of medical treatment for endometriosis (i.e., the 
effect of hormonal therapies in relation to the resources they consume), costly drugs should be 
used solely when safe and inexpensive medications are ineffective, not tolerated, or 
contraindicated. Based on a recently proposed stepped-care approach for the management of 
symptomatic endometriosis [15], very-low-dose oral contraceptives and low-cost progestins 
should be used first, stepping up to dienogest, a high-cost progestin, and then to GnRH 
agonists selectively in non-responders. Laparoscopy should be considered when drugs fail or 
when informed women prefer surgery over hormonal treatments. Such an approach would 
greatly reduce the direct cost for long-term endometriosis management. 
 According to the NICE Guideline Committee, empirical diagnosis followed by 
cheaper hormonal treatments was extremely likely to be the most cost-effective therapeutic 
strategy [12]. The quality of the evidence was not sufficient to recommend COCs over 
progestins, although COCs generated slightly more quality-adjusted life-years on average. 
Moreover, the Committee suggested to give priority to women's preferences regarding the 
type of cheap hormonal treatment to use.  
4. Reducing low-value surgical treatment 
Costs and harms of endometriosis management may be here increased by: i) systematically 
pursuing surgery to relieve pain and performing bowel resection when not strictly clinically 
indicated [7]; ii) using costly instrumentation such as the surgical robot [18]; iii) not 
preventing postoperative recurrences medically [10]. 
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 i) According to Soliman et al. [2], surgery greatly impacts on direct costs of 
endometriosis. When pelvic pain is the issue, and no large adnexal masses or ureteral and 
bowel stenosis are present, surgery is always optional, never mandatory. Performing surgery 
selectively when medical treatment is not effective, not tolerated, contraindicated, or declined, 
greatly limits costs of management. Moreover, colorectal resection is the single pelvic 
procedure associated with the highest risk of severe complication (5-10%), including 
anastomotic dehiscence, rectovaginal fistula formation, ureteral damage, and bladder/bowel 
denervation [8]. If an endometriotic bowel nodule does not cause manifest sub-occlusion, 
rectosigmoid resection should be considered with caution, being associated with undefined 
benefits, definite harms, and increased direct and indirect costs. 
 ii) The impact of robotic surgery on direct healthcare costs are impressive, 
although it does not improve outcomes of endometriosis patients [16]. The American College 
of Obstetricians and Gynecologists included an item on robotic surgery in benign gynecology 
in its “Choosing Wisely” list. The College discourages the use of the daVinci robot, 
suggesting a standard laparoscopic approach, due to lack of advantages of robotic surgery in 
terms of perioperative outcomes, intraoperative complications, length of hospital stay and rate 
of conversion to open surgery, and evidence of disadvantages in terms of operating time and 
costs [17]. This view is shared by the American Association of Gynecologic Laparoscopists 
[18]. 
 iii) Endometriosis has a marked relapsing tendency [9,10]. Surgery eliminates 
lesions, but does not eliminate the pathogenic factors that predispose to implantation of 
endometrium at ectopic sites. When COCs or progestins are used postoperatively, the risk of 
symptom and lesion recurrence is reduced by 80-90% [9,10]. This safe and inexpensive 
preventive measure may safeguard the already damaged reproductive potential, reduce 
morbidity, and contain costs. According to the NICE Guideline Committee, the addition of 
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hormonal treatment to delay the recurrence of endometriosis is an important health economic 
issue, as "for example, doubling average recurrence time would halve the number of 
operations required to treat a woman over the course of her lifetime, with clear cost 
implications" [12]. Based on the economic analysis model adopted, cheaper hormonal 
treatments like COCs were likely to be more cost-effective, and should be used in women not 
trying to conceive or in those who were planning pregnancy in the future. 
5. Minimally disruptive endometriosis management: reducing the burden of 
treatment 
The International Minimally Disruptive Medicine Workgroup consider that patients affected 
by chronic diseases must face not only the burden of illness (e.g., symptoms and fatigue), but 
also the burden of treatment (e.g., visits to the physician, various types of tests, drug intake, 
self-monitoring, lifestyle changes, administrative tasks to access and coordinate care) [19,20]. 
Hidden costs, full or part payment of treatments, and the potential psychosocial burden of 
being medicalized and turned into a patient also should be considered [19]. 
 “Minimally disruptive medicine” is an approach to providing high-value care that 
emphasizes individual priorities, at the same time minimizing the workload for patient and 
caregiver [19]. Modifying treatments taking into account the burden of treatment has the 
potential to improve outcomes [20]. According to Spencer-Bonilla et al. [20], "ultimately, the 
value of care for patients should reflect the health outcomes achieved and the degree of 
burden that patients and their caregivers must bear to achieve those outcomes". 
 Organizing high-quality, high-value, patient-centered endometriosis care requires 
awareness of both, the burden of illness and the burden treatment. Limiting laparoscopy for 
diagnostic purposes, suggesting long-term treatments with cheap and well-tolerated COCs 
and progestins without delay, avoiding unnecessary surgical procedures, preventing symptom 
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and lesion recurrence via prolonged ovarian suppression, divesting from unjustifiably costly 
medical practices, and systematically adopting a stepped-care approach, has the potential to 
decrease the burden of treatment (e.g., the number of gynecological visits, imaging 
examinations, laboratory exams, frequency of re-operations), and improve outcomes for 
patients, at the same time limiting the progressive rise in costs for endometriosis management 
[7,8,15].  
 Finally, value-based assessment of health technologies appears crucial in order not to 
violate equity. According to Paulden, new technologies should no longer recommended 
"unless the value of the expected health gains exceeds the value of the expected health losses" 
[21]. In fact, given the fixed budget of national health services, costly technologies displace 
resources in other similar patients, with a net reduction in population health. Thus, the 
adoption of costly diagnostic and treatment modalities that do not consistently and 
substantially improve health outcomes of endometriosis patients, are implicitly inequitable 
towards other patients and society at large. 
Funding  
This study was financed by Italian fiscal contribution "5x1000" - Ministero dell'Istruzione, 
dell'Università e della Ricerca - devolved to Fondazione Istituto di Ricovero e Cura a 
Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.  
 
 
 
 
Declaration of Interest  
D
ow
nl
oa
de
d 
by
 [R
M
IT
 U
niv
ers
ity
 L
ibr
ary
] a
t 0
0:3
9 0
2 D
ec
em
be
r 2
01
7 
Ac
ce
pte
d M
an
us
cri
pt
 
The authors have no relevant affiliations or financial involvement with any organization or 
entity with a financial interest in or financial conflict with the subject matter or materials 
discussed in the manuscript. This includes employment, consultancies, honoraria, stock 
ownership or options, expert testimony, grants or patents received or pending, or royalties. 
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose. 
REFERENCES 
1. Gylfason JT, Kristjansson KA, Sverrisdottir G, Jonsdottir K, Rafnsson V, Ge rsson 
RT. Pelvic endometriosis diagnosed in an entire nation over 20 years. Am J Epidemiol 
2010;172:237–43. 
2. Soliman AM, Yang H, Du EX, Kelley C, Winkel C. The direct and indirect costs 
associated with endometriosis: a systematic literature review. Hum Reprod. 2016;31:712-22. 
3. Leyland N, Casper R, Laberge P, Singh SS; SOGC. Endometriosis: diagnosis and 
management. J Obstet Gynecol Can 2010;32:S1-32.   
4. American College of Obstetricians and Gynecologists. Management of endometriosis. 
ACOG practice bulletin no. 114. Obstet Gynecol 2010;116:223–36.  
5. Practice Committee of the American Society for Reproductive Medicine. Treatment of 
pelvic pain associated with endometriosis: a committee opinion. Fertil Steril 2014;101:927–
35. 
6. Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, et 
al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014;29:400-
12.  
D
ow
nl
oa
de
d 
by
 [R
M
IT
 U
niv
ers
ity
 L
ibr
ary
] a
t 0
0:3
9 0
2 D
ec
em
be
r 2
01
7 
Ac
ce
pte
d M
an
us
cri
pt
 
7. Vercellini P, Giudice LC, Evers JL, Abrao MS. Reducing low-value care in 
endometriosis between limited evidence and unresolved issues: a proposal. Hum Reprod 
2015;30:1996-2004. 
8. Vercellini P, Facchin F, Buggio L, Barbara B, Berlanda N, Frattaruolo MP, 
Somigliana E. Management of endometriosis: toward value-based, cost-effective, affordable 
care. J Obstet Gynecol Can 2017; in press. 
9. Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update 
2009;15:441-61.  
10. Koga K, Takamura M, Fujii T, Osuga Y. Prevention of the recurrence of symptom and 
lesions after conservative surgery for endometriosis. Fertil Steril 2015;104:793-801. 
11. Vercellini P, Bracco B, Mosconi P, Roberto A, Alberico D, Dhouha D, Somigliana E. 
Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before 
and after study. Fertil Steril 2016;105:734-43.e3. 
12. National Institute for Health and Care Excellence. Endometriosis: diagnosis and 
management (NICE guideline 73). 2017. https://www.nice.org.uk/Guidance/NG73/evidence 
(accessed on September 9, 2017). 
13. Nisenblat V, Bossuyt PM, Farquhar C, Johnson N, Hull ML. Imaging modalities for 
the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev. 
2016;2:CD009591. doi:10.1002/14651858.CD009591.pub2. 
14. Guerriero S, Condous G, van den Bosch T, Valentin L, Leone FP, Van Schoubroeck 
D, et al. Systematic approach to sonographic evaluation of the pelvis in women with 
suspected endometriosis, including terms, definitions and measurements: a consensus opinion 
D
ow
nl
oa
de
d 
by
 [R
M
IT
 U
niv
ers
ity
 L
ibr
ary
] a
t 0
0:3
9 0
2 D
ec
em
be
r 2
01
7 
Ac
ce
pte
d M
an
us
cri
pt
 
from the International Deep Endometriosis Analysis (IDEA) group. Ultrasound Obstet 
Gynecol. 2016;48:318-32. 
15. Vercellini P, Buggio L, Somigliana E. The role of medical therapy in the management 
of deep rectovaginal endometriosis. Fertil Steril 2017, in press.  
16. Berlanda N, Frattaruolo MP, Aimi G, Farella M, Barbara G, Buggio L, Vercellini P. 
“Money for nothing” The role of robotic assisted laparoscopy for the treatment of 
endometriosis. Reprod Biomed Online. 2017 May 30. pii: S1472-6483(17)30242-0. doi: 
10.1016/j.rbmo.2017.05.010. [Epub ahead of print] 
17. American College of Obstetricians and Gynecologists. Ten things physicians and 
patients should question. Choosing Wisely. An initiative of the ABIM Foundation. Released 
March 14, 2016 (Items 6–10). Recommendation #6 revised August 24, 2016: 
http://www.choosingwisely.org/societies/american-college-of-obstetricians-and-
gynecologists/ (accessed on September 9, 2017). 
18. American Association of Gynecologic Laparoscopists. AAGL position statement: 
robotic-assisted laparoscopic surgery in benign gynecology. J Minim Invasive Gynecol 
2013;20:2-9. 
19. Mair FS, May CR. Thinking about the burden of treatment. BMJ 2014;349:g6680. 
20. Spencer-Bonilla G, Quiñones AR, Montori VM; International Minimally Disruptive 
Medicine Workgroup. Assessing the Burden of Treatment. J Gen Intern Med. 2017 Jul 11. 
doi: 10.1007/s11606-017-4117-8. [Epub ahead of print] 
21. Paulden M. Recent amendments to NICE's value-based assessment of health 
technologies: implicitly inequitable? Expert Rev Pharmacoecon Outcomes Res 2017;17:239- 
D
ow
nl
oa
de
d 
by
 [R
M
IT
 U
niv
ers
ity
 L
ibr
ary
] a
t 0
0:3
9 0
2 D
ec
em
be
r 2
01
7 
Ac
ce
pte
d M
an
us
cri
pt
 
Table 1. Cost of one year of continuous medical treatment for endometriosis. Italy, 2017 
__________________________________________________________________________ 
Medication       Cost 
      €  £  $ 
__________________________________________________________________________ 
Depot GnRH agonists   1840  1693  2190 
Dienogest 2 mg os/day     730    672    861 
Estrogen-progestin vaginal ring    338    311    402 
Estrogen-progestin transdermal patch   278    256    331 
Danazol 200 mg per vaginam/day    275    253    327 
Very-low-dose monophasic COCs*    159-167   146-158    188-197 
Levonorgestrel-releasing IUD†      48      44      57 
Nor-ethisterone acetate 2.5 os/day      17      16       20 
__________________________________________________________________________ 
*COC = combined oral contraceptive. 
†IUD = intrauterine device. 
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